PET Imaging for Response Assessment in Lymphoma: Potential and Limitations

Heiko Schöder, Craig Moskowitz

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered the most accurate tool for the assessment of treatment response and prognosis in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This article discusses the potential and limitations of FDG-PET for response assessment in malignant lymphoma during chemotherapy (interim PET) and at the end of chemotherapy. Interim PET is used to predict the likelihood for a complete response at the end of such therapy. End-of-treatment PET aims to establish the completeness of response or the presence of residual viable tumor tissue. Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols.

Original languageEnglish (US)
Pages (from-to)225-241
Number of pages17
JournalRadiologic Clinics of North America
Issue number2
StatePublished - Mar 2008
Externally publishedYes


  • FDG
  • Lymphoma
  • PET
  • PET-CT
  • Response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET Imaging for Response Assessment in Lymphoma: Potential and Limitations'. Together they form a unique fingerprint.

Cite this